PT89062A - Processo para a preparacao de conjugados de anticorpos monoclonais-farmacos com actividade antitumor - Google Patents

Processo para a preparacao de conjugados de anticorpos monoclonais-farmacos com actividade antitumor

Info

Publication number
PT89062A
PT89062A PT89062A PT8906288A PT89062A PT 89062 A PT89062 A PT 89062A PT 89062 A PT89062 A PT 89062A PT 8906288 A PT8906288 A PT 8906288A PT 89062 A PT89062 A PT 89062A
Authority
PT
Portugal
Prior art keywords
pharmacos
conjugates
preparation
monoclonal antibodies
drug
Prior art date
Application number
PT89062A
Other languages
English (en)
Other versions
PT89062B (pt
Inventor
Peter D Senter
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT89062A publication Critical patent/PT89062A/pt
Publication of PT89062B publication Critical patent/PT89062B/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
PT89062A 1987-11-23 1988-11-23 Processo para a preparacao de conjugados de anticorpos monoclonais-farmacos com actividade antitumor PT89062B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/124,313 US4952394A (en) 1987-11-23 1987-11-23 Drug-monoclonal antibody conjugates

Publications (2)

Publication Number Publication Date
PT89062A true PT89062A (pt) 1989-11-30
PT89062B PT89062B (pt) 1993-07-30

Family

ID=22414122

Family Applications (1)

Application Number Title Priority Date Filing Date
PT89062A PT89062B (pt) 1987-11-23 1988-11-23 Processo para a preparacao de conjugados de anticorpos monoclonais-farmacos com actividade antitumor

Country Status (16)

Country Link
US (1) US4952394A (pt)
EP (1) EP0317957B1 (pt)
JP (1) JPH02111731A (pt)
KR (1) KR910005887B1 (pt)
AT (1) ATE81986T1 (pt)
AU (1) AU617380B2 (pt)
CA (1) CA1303524C (pt)
DE (1) DE3875700T2 (pt)
DK (1) DK651088A (pt)
FI (1) FI885361A7 (pt)
GR (1) GR3006211T3 (pt)
IL (1) IL88428A0 (pt)
NO (1) NO169958C (pt)
NZ (1) NZ226955A (pt)
PT (1) PT89062B (pt)
ZA (1) ZA886811B (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5155210A (en) * 1990-09-11 1992-10-13 Brunswick Corporation Methods of conjugating actinomycin d
EP0510132B1 (en) * 1990-09-28 1997-05-14 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5776458A (en) * 1990-12-05 1998-07-07 Pharmacia & Upjohn S.P.A. Anthracycline-conjugates
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU701529B2 (en) * 1994-04-05 1999-01-28 Purdue Research Foundation NADH oxidase as a target in diagnosis and therapy
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6299860B1 (en) * 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
JP2002542386A (ja) * 1999-04-23 2002-12-10 アルザ・コーポレーション 放出可能な結合及びこれを含む組成物
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
KR100669053B1 (ko) 1999-04-23 2007-01-15 알자 코포레이션 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트
CN1110322C (zh) * 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'-平阳霉素偶联物及其抗肿瘤作用
AU2001227679A1 (en) * 2000-02-25 2001-09-03 General Atomics Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
WO2001071352A2 (en) * 2000-03-17 2001-09-27 The Salk Institute For Biological Studies Compositions associated with complex formation
US6610504B1 (en) 2000-04-10 2003-08-26 General Atomics Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
JP2004514409A (ja) * 2000-05-10 2004-05-20 ブリストル−マイヤーズ スクイブ カンパニー 修飾イノシン5’−一リン酸デヒドロゲナーゼポリペプチドおよびその用途
JP2004536027A (ja) 2000-12-01 2004-12-02 ジョーンズ・ホプキンス・ユニーバーシティー グリコシル化/ガラクトシル化ペプチドの接合体、二官能性リンカー、およびヌクレオチドのモノマー/ポリマー、および関連する組成物および使用方法
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
MXPA03011094A (es) * 2001-05-31 2004-12-06 Medarex Inc Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7384760B2 (en) * 2004-04-30 2008-06-10 General Atomics Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
NZ550934A (en) * 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
AU2005281359A1 (en) * 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
HRP20120709T1 (hr) * 2005-02-18 2012-10-31 Medarex, Inc. Humano monoklonsko protutijelo za prostata-specifiäśni membranski antigen (psma)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
CA2623652C (en) * 2005-09-26 2013-11-26 Medarex, Inc. Antibody-drug conjugates and methods of use
AU2006305842B2 (en) 2005-10-26 2011-11-03 E. R. Squibb & Sons, L.L.C. Methods and compounds for preparing CC-1065 analogs
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
CN101616911A (zh) * 2007-02-21 2009-12-30 梅达莱克斯公司 具有单个氨基酸的化学连接物及其偶联物
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
JP2010527618A (ja) 2007-05-24 2010-08-19 アメリカ合衆国 ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
CA2699912A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
KR101666631B1 (ko) 2008-05-27 2016-10-17 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체
ES2647351T3 (es) 2008-12-05 2017-12-21 Abraxis Bioscience, Llc Péptidos de unión a SPARC y usos de los mismos
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US8399219B2 (en) * 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
EP2438090B1 (en) 2009-05-28 2016-07-06 The United States Government as Represented by the Department of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
CN105849086B (zh) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
EP4008729A1 (en) 2014-11-05 2022-06-08 Nanyang Technological University Stabilized and autonomous antibody vh domain
FI3319936T3 (fi) 2015-07-12 2026-03-12 Hangzhou Dac Biotech Co Ltd Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US11590242B2 (en) 2016-06-15 2023-02-28 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
KR20220147721A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
EP4079327A1 (en) * 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ, インコーポレイテッド 免疫エフェクター機能を有する操作されたvlrb抗体
US20240400627A1 (en) 2021-09-30 2024-12-05 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 抗体の特異的共役
US20260071003A1 (en) 2022-09-01 2026-03-12 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024064752A2 (en) 2022-09-20 2024-03-28 Yale University Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates
EP4655007A1 (en) 2023-01-23 2025-12-03 Yale University Antibody oligonucleotide conjugates
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPH0651643B2 (ja) * 1983-01-19 1994-07-06 帝人株式会社 殺細胞性修飾免疫グロブリン及びその製造方法
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound

Also Published As

Publication number Publication date
EP0317957B1 (en) 1992-11-04
NO885199L (no) 1989-05-24
KR910005887B1 (ko) 1991-08-06
DE3875700D1 (de) 1992-12-10
NZ226955A (en) 1991-11-26
US4952394A (en) 1990-08-28
GR3006211T3 (pt) 1993-06-21
CA1303524C (en) 1992-06-16
IL88428A0 (en) 1989-06-30
NO885199D0 (no) 1988-11-22
DK651088D0 (da) 1988-11-22
FI885361A0 (fi) 1988-11-18
EP0317957A2 (en) 1989-05-31
ZA886811B (en) 1989-07-26
FI885361L (fi) 1989-05-24
NO169958B (no) 1992-05-18
ATE81986T1 (de) 1992-11-15
JPH02111731A (ja) 1990-04-24
KR890007724A (ko) 1989-07-05
AU617380B2 (en) 1991-11-28
EP0317957A3 (en) 1989-07-05
PT89062B (pt) 1993-07-30
DK651088A (da) 1989-05-24
AU2582488A (en) 1989-05-25
FI885361A7 (fi) 1989-05-24
NO169958C (no) 1992-08-26
DE3875700T2 (de) 1993-03-18

Similar Documents

Publication Publication Date Title
PT89062A (pt) Processo para a preparacao de conjugados de anticorpos monoclonais-farmacos com actividade antitumor
PT88187A (pt) Metodo para a distribuicao de agentes citotoxicos para celulas tumorais mediante administracao de conjugados de anticorpo-enzima em associacao com profarmacos com actividade citotoxica
ATE122679T1 (de) Amin-derivate von anthracyclin-antibiotika.
PT947222E (pt) Metodo de activacao de agentes fotossensiveis
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
PT93966A (pt) Novo sistema de libertacao de anticorpos para modificadores de resposta biologica
NO178928C (no) Analogifremgangsmåte for fremstilling av et terapeutisk aktivt konjugat av rhodiumkompleks
ZA877153B (en) Recombinant pseudomonas exotoxins:construction of an active immunotoxin with low side effects
PT91201A (pt) Novos metodos para produzir anticorpos monoclonais aperfeicoados reactivos com a caquectina
ATE105484T1 (de) Aminderivate von folsaeure analogen.
PT97423A (pt) Processo para a preparacao de composicoes farmaceuticas contendo conjugados de anticorpos para o tratamento de neoplasias
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
ATE113470T1 (de) Gehirnspezifische zubereitung mit gesteuerter abgabe.
FI891718A0 (fi) Foerfarande foer att befria cellblandningar och vaevnader av icke-oenskade populationer.
DE3881254D1 (de) Pharmazeutische zusammensetzung.
ES2079345T3 (es) Administracion subcutanea de gonadotropina corionica humana.
IT8026232A0 (it) Composizioni farmaceutiche. derivato dell'alfa-mercapto propionilglicina ad attivita'terapeutica, procedimento per lasua preparazione e relative
KR880011328A (ko) 신규 화합물들
DK328189D0 (da) Konjugater mellem et laegemiddel og en nitrophenylgruppe samt farmaceutisk anvendelse deraf
BR9609937A (pt) Composição contendo ácido mefenâmico em associação com codeìna

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19930115